Metrics as of 10/16/2026, 02:05 AM (Berlin time), refresh in progress.
Rein Therapeutics Stock
Rein Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- James Brian Windsor
- Employees
- 10
- Market cap
- $18 M
- IPO
- 29/06/2017
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by…
Rein Therapeutics stock: price history
1D
+7.2%
1W
-18.4%
1M
-11.2%
6M
-63.1%
YTD
-45.9%
1Y
-51.7%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~25% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Rein Therapeutics
Analyst assessment of Rein Therapeutics
PRICE TARGET LOW
US$6.00
CONSENSUS
US$6.00
MEDIAN
US$6.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
1
BUY
1
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 18/08/2026
Rein Therapeutics stock metrics
P/E
-0.34
P/B
1.87
EV/EBITDA
-0.43
RETURN ON EQUITY
-62.5%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
76.4%
FLOAT SHARES
21,345,835
AVG. DAILY VOLUME (30D)
441,411
Insider transactions (SEC)
VON RICKENBACH JOSEF H
VON RICKENBACH JOSEF H
VON RICKENBACH JOSEF H
VON RICKENBACH JOSEF H
WINDSOR JAMES BRIAN
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Rein Therapeutics stock
What does Rein Therapeutics do?
Rein Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is James Brian Windsor, the company employs around 10 people.
The IPO was on 29/06/2017; the stock trades on NASDAQ under the ticker RNTX.
What do analysts say about Rein Therapeutics stock?
2 analysts rate the stock, the consensus is Buy (as of 18/08/2026).
The average price target is US$6.00, ranging from US$6.00 to US$6.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
When does Rein Therapeutics report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -25% stronger than usual.
Does Rein Therapeutics pay a dividend?
No, Rein Therapeutics currently does not pay a dividend.
Which stocks are comparable to Rein Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Rein Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Rein Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.